Skip to main content
. 2024 Jan 17;12(1):101214. doi: 10.1016/j.gendis.2024.101214

Figure 4.

Figure 4

CDC5L mediates the proliferative effect of IGF2BP1 in MM cells. (A) Compared with NCI-H929-IGF2BP1-NC cells, NCI-H929-IGF2BP1-OE cells had increased expression of CDC5L protein, as shown by western blot results. Compared with RPMI-RPMI-8226-IGF2BP1-NC cells, RPMI-RPMI-8226-IGF2BP1-KD cells had less expression of CDC5L protein. (B) IGF2BP1 expression did not affect the stability of CDC5L mRNA. NCI-H929 cells were treated with actinomycin D at the indicated time durations, and CDC5L mRNA levels were quantitated by quantitative PCR. (C) Cell cycle assays showed that knockdown of CDC5L would result in S-phase arrest. (D) The ratio of EdU-positive cells (green) in the RPMI-RPMI-8226-CDC5L-KD group was found to be significantly lower than in the control group. (E) An IGF2BP1/OE-CDC5L/KD rescue cell line was constructed. (F) Knockdown of CDC5L attenuated the proliferative effect of IGF2BP1 on NCI-H929 cells by CCK8 assays (∗∗∗P < 0.001). (G)In vivo, we assessed the growth disparities among IGF2BP1/NC-CDC5L/NC, IGF2BP1/OE-CDC5L/NC, and IGF2BP1/OE-CDC5L/KD cells after subcutaneously inoculating these cells to B-NDG mice. CDC5L, cell division cycle 5-like; IGF2BP1, insulin-like growth factor 2 mRNA binding protein 1; MM, multiple myeloma.